Trial Profile
A Study Evaluating Real-World Clinical and Economic Outcomes of Lenalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma Without Stem Cell Transplant
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jan 2019
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 04 Dec 2018 Results (Patients were from Flatiron Health database between Jan 2011 and May 2018) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 20 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association.